Indian Journal of Hematology and Blood Transfusion最新文献

{"title":"A Survey to Assess the Knowledge and Perceptions about Gene Therapy in Indian Haemophilia Patients.","authors":"Shruti Kharat, Shreyas Tawde, Cecil Ross, M Joseph John, Shruti Dabhade, Shrinath Kshirsagar, Kranti Patil, Gurpreet Kaur Saini, Apurva More, Nazish Kaunchale, Diksha Sarwan, Mridul Makkar, Magdalene D'silva, Shrushti Masurkar, Savita Rangarajan, Kalpana Hajirnis, Shrimati Shetty","doi":"10.1007/s12288-024-01945-1","DOIUrl":"https://doi.org/10.1007/s12288-024-01945-1","url":null,"abstract":"<p><p>Novel molecules including gene therapy are used to treat haemophilia. Little is known on patient perceptions about gene therapy. Present survey is to assess the knowledge and identify key educational gaps and concerns about gene therapy in Indian persons with haemophilia (PWH). An explorative, qualitative, closed questionnaire based survey was conducted recruiting adult PWH from 3 Centers in India. Data were collected through face-to-face surveys or the patients themselves filling the survey forms. Of the 415 complete questionnaires received from adult severe PWH, approximately half of the PWH felt that gene therapy is the best option for PWH, but only 31.2% showed their willingness to be a part of any gene therapy clinical trial, if available. About 57% of the PWH were unable to decide about participation in clinical trials and 11.7% of the participants would never consider receiving gene therapy. Major concerns were cost, side effects, duration of expression and rejection, infection and risk of liver cancer. The PWH expressed their desire for information on subjects like eligibility criteria, earlier trial data, and details on safety. The survey shows a low level of knowledge about gene therapy in PWH and identifies gaps in knowledge and a strong willingness to understand more on the potential risk: benefit profile of gene therapy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12288-024-01945-1.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"873-877"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Remission in a Case of Acute Promyelocytic Leukaemia with Coexistent t(15;17) and t(8;21) Without Chemotherapy.","authors":"Rudra Narayan Swain, Sarthak Wadhera, Charanpreet Singh, Arihant Jain, Gaurav Prakash, Shano Naseem, Alka Khadwal, Jasmina Ahluwalia, Pankaj Malhotra","doi":"10.1007/s12288-024-01939-z","DOIUrl":"https://doi.org/10.1007/s12288-024-01939-z","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"1025-1027"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparable Short Term Outcomes Among Patients with Newly Diagnosed Acute Myeloid Leukemia with or without Myelodysplasia Related Gene Mutations Treated with Azacytidine-Venetoclax: Observations from a Single Center Retrospective Cohort.","authors":"Rudra Narayan Swain, Sarthak Wadhera, Charanpreet Singh, Deepesh Lad, Shano Naseem, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra, Arihant Jain","doi":"10.1007/s12288-024-01944-2","DOIUrl":"https://doi.org/10.1007/s12288-024-01944-2","url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) is a heterogeneous hematologic malignancy, and up to 50% of cases are classified as cytogenetically normal AML (CNAML). The 2022 European Leukemia Net (ELN) guidelines identify Myelodysplasia Related(MR) gene mutations, such as ASXL1 and RUNX1, as adverse risk factors, particularly in patients treated with intensive chemotherapy. However, limited data exist regarding the prognostic impact of MR mutations in CN-AML patients managed with Azacytidine and Venetoclax (Aza+Ven) based induction. In the current study, consecutive patients with newly diagnosed CN- AML treated at one centre were classified as MR positive and negative on the basis of the presence and absence of MR mutations respectively. Clinical data, including patient demographics and treatment onsecutivet responses, were systematically recorded, and the cytogenetic and molecular data were analyzed to correlate these findings with clinical outcomes, such as complete remission rates and overall survival. Fifty three consecutive newly diagnosed AML patients treated with Aza+Ven were screened. Thirty two patients having CN-AML were included in the current analysis. The CR/CRi rates were comparable between MR mutated and MR unmutated groups (80% vs. 70%, <i>p</i>=0.5). The proportion of patients attaining MRD negativity after the first cycle was not significantly different [MR mutated (3/10, 30%) versus MR unmutated (7/22, 31%); (<i>P</i> = 0.95)] amongst the two groups. Median progression-free survival (PFS) and overall survival (OS) was not significantly different between MR mutated and MR unmutated groups (not reached vs. 12 months, <i>p</i>=0.437 and <i>p</i>=0.136,; HR-0.53, 0.22;p-0.45,0.17 respectively). Our findings, support that the presence of MR mutations may not adversely impact treatment outcomes when treated with Aza+Ven treatment regimen.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"987-991"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct Antiglobulin Test Positivity in Blood Donors and Impact on Donor Health and Transfusion Services: A Seven-Year Retrospective Study from Eastern India.","authors":"Durba Biswas, Najla H Basheela, Rashmi K Pandey, Debapriya Basu, Suvro Sankha Datta","doi":"10.1007/s12288-025-01996-y","DOIUrl":"https://doi.org/10.1007/s12288-025-01996-y","url":null,"abstract":"<p><p>The aim of this study is to determine the incidence of a positive direct antiglobulin test (DAT) in a population of blood donors in Eastern India and to explore the impact of DAT positivity on donor health and transfusion services. We conducted a retrospective study on 89,402 blood donors over a seven-year period (2018-2024). Positive DAT results were detected using the column agglutination technique (CAT) following a difficulty in the cross-match, a positive weak D test on donor RhD typing, and a positive autocontrol encountered during donor antibody screening. Furthermore, DAT was subclassified, and donors exhibiting a DAT strength of ≥ 2 + were recalled and investigated. We found the DAT was positive in 54 donors (0.06%) with an overall incidence of 1:1,656. The DAT-positive donors presented predominantly as crossmatch incompatibility (85.2%). The majority of blood donors (96.3%) were IgG positive. Of the 39 donors who were evaluated, two were found to have autoimmune diseases. The remaining donors showed no signs of hemolysis and were in good health. The incidence of positive DAT results in eastern Indian blood donors is higher, leading to increasing non-utilization of collected blood units. There is a need for a national policy for managing DAT-positive donors in India.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"978-982"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemangioma as a Primary Manifestation of POEMS Syndrome.","authors":"Punit Jain, Yovan Mahadeb, Gautam Dethe, Kanika Khandelwal, Anand Zade, Veena Vanere","doi":"10.1007/s12288-025-01980-6","DOIUrl":"https://doi.org/10.1007/s12288-025-01980-6","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"1032-1033"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Dasatinib on Female Reproductive Health in Philadelphia-Positive Leukemia Patients.","authors":"Shamita Kintada, Vanita Suri, Aashima Arora, Nalini Gupta, Tulika Singh, Naresh Sachdeva, Arihant Jain, Alka Khadwal, Pankaj Malhotra","doi":"10.1007/s12288-024-01932-6","DOIUrl":"https://doi.org/10.1007/s12288-024-01932-6","url":null,"abstract":"<p><p>Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), with patients now achieving life expectancy comparable to the general population. Despite the contraindication of TKIs during the first trimester of pregnancy, their effects on female reproductive health remain underexplored. This pilot case-control study evaluated the impact of Dasatinib on the female reproductive system in 25 women with CML or Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), compared to 25 age-matched controls. Clinical histories, gynecological examinations, transvaginal ultrasonography, and serum Anti-Müllerian hormone (AMH) assessments were performed. There was no significant differences in menstrual cycle characteristics between patients and controls, although 12% of patients experienced shorter cycles and 8% reported heavier menstrual flow after initiating Dasatinib. Notably, patients on Dasatinib had significantly lower serum AMH levels (<i>p</i> < 0.005) and a higher incidence of low antral follicle count (AFC < 5 mm). Abnormal cervical cytology was observed in one patient, and two tested positive for HPV DNA. Dasatinib may subtly but significantly affect ovarian reserve and cervical health. Larger studies are needed to clarify these reproductive effects and inform clinical management in women receiving Dasatinib therapy.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"947-950"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Systemic Inflammatory Indices in Predicting Composite Adverse Outcomes of Peripartum Hemorrhage Treated with Fibrinogen Concentrate.","authors":"Eda Ozden Tokalioglu, Atakan Tanacan, Merve Ozturk Agaoglu, Onur Özkavak, Aysegul Atalay, Petek Uzuner, Dilek Sahin","doi":"10.1007/s12288-024-01905-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01905-9","url":null,"abstract":"<p><p>Hematological systemic inflammatory markers have been used in predicting the severity and prognosis of the disease in recent years. We aimed to determine the value of neutrophil to lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and platelet to lymphocyte ratio (PLR) in the prediction of composite adverse outcomes (CAO) in peripartum hemorrhage requiring fibrinogen administration. This retrospective cohort study was conducted with pregnant women who were treated with perioperative fibrinogen concentrate in the Department of Perinatology, Ministry of Health Ankara City Hospital between January 01, 2023 and June 01, 2023. NLR (neutrophil/lymphocyte), PLR (platelet/lymphocyte), and SII (NLR x platelet count) were calculated using the complete blood cell count at the first hospital admission. Patients were divided into two groups based on the presence (<i>n</i> = 31) or absence (<i>n</i> = 60) of a composite adverse outcome. NLR, PLR, and SII values were compared between the two subgroups. We used receiver operating characteristic (ROC) curves to assess the performance of complete blood cell indices to predict CAOs. Statistically significantly higher values for NLR, PLR, and SII were observed in the CAO group (<i>p</i> < 0.05). Optimal cut-off values were 774.42 (70.5% sensitivity, 47.7% specificity, <i>p</i> < 0.001), 103.09 (78.7% sensitivity, 53.3% specificity, <i>p</i> < 0.001), and 3.33 (73.8% sensitivity, 50% specificity, <i>p</i> < 0.001), for Sİİ, PLR, and NLR, respectively. NLR, PLR and SII are non-invasive, low-cost, simple and repeatable indices. These indices could help clinicians identify patients at high-risk for CAO in severe postpartum hemorrhage and customise individualised therapeutic regimens.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"934-941"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kissing Triangles: A Peculiar Pattern of Hemoglobin Camden in Capillary Zone Electrophoresis.","authors":"Ekta Jajodia, Avinash Panchal, Neeraj Arora, Mohan Galande, Ankita Desai, Ankit Jitani","doi":"10.1007/s12288-024-01957-x","DOIUrl":"https://doi.org/10.1007/s12288-024-01957-x","url":null,"abstract":"","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"1030-1031"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of TNF α and IL-6 Levels in Indian Patients of CML and their Correlation with Early Molecular Response: An Observational Study.","authors":"Mohit Sahu, Sumita Chaudhry, Monica Sharma, Sumita Saluja, Aditi Jain, Ankur Jain","doi":"10.1007/s12288-024-01947-z","DOIUrl":"https://doi.org/10.1007/s12288-024-01947-z","url":null,"abstract":"<p><p>The study aimed to study the correlation of inflammatory cytokines TNF α and IL6 with early molecular response (EMR) in Indian CML patients on Imatinib. Methods-A tertiary hospital based cross sectional observational study included 47 patients with newly diagnosed CML over a period of 18 months. Plasma levels of TNFα and IL6 along with levels of BCR-ABL were done at baseline and at 3 month of therapy. Results- TNFα at baseline was the better predictor of EMR not achieved at cut off point of > 109 pg/ml and IL6 at 3 month was the better predictor of EMR not achieved at cut off point of > 45 pg/ml Conclusion- The combination of high TNF and IL-6 levels at baseline and at 3 months identifies a high risk subset of CML patients with significantly lower EMR. Mesurement of these cytokines at above time points may allow treatment intensity to be individualised based on the patient's risk profile.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"836-842"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchus-Associated Lymphoid Tissue Lymphoma (BALToma) Treated as Pulmonary Tuberculosis Presenting with Stridor.","authors":"Srikant K Malegaonkar","doi":"10.1007/s12288-025-01974-4","DOIUrl":"https://doi.org/10.1007/s12288-025-01974-4","url":null,"abstract":"<p><p>Bronchus-Associated Lymphoid Tissue Lymphoma (BALToma) is a rare extranodal B cell neoplasm with non-specific clinical and radiological manifestations, therby resulting in erroneous plus delayed diagnosis. Herein we present the case of a middle aged lady who was on anti tubercular treatment for her constitutional symptoms and was referred to us for management of new onset stridor. BALToma diagnosis was made after detailed evaluation of this patient and she had excellent to chemotherapy.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"1034-1036"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}